Viral evolution and escape during primary human immunodeficiency virus-1 infection: Implications for vaccine design

Current Opinion in HIV and AIDS

Volumn 3, Issue 1, 2008, Pages 60-66

  Mullins, James I ^a   Rolland, Morgane ^a   Allen, Todd M ^b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Evolution; HIV; T lymphocyte; Viral proteins

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; DRUG DESIGN; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MOLECULAR EVOLUTION; PRIMARY INFECTION; PRIORITY JOURNAL; PROTEIN STRUCTURE; REVIEW; SEQUENCE ANALYSIS; T LYMPHOCYTE; VIRUS MUTATION; VIRUS REPLICATION;

EID: 40349091096     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e3282f233d9     Document Type: Review

References (72)

1. Mullins JI. Curtailing the AIDS pandemic. Science 1997; 276:1955-1957.
2. Johnston MI, Fauci AS. An HIV vaccine - evolving concepts. N Engl J Med 2007; 356:2073-2081.
3. Gupta SB, Jacobson LP, Margolick JB, et al. Estimating the benefit of an HIV-1 vaccine that reduces viral load set point. J Infect Dis 2007; 195:546-550.
4. Stover J, Bollinger L, Hecht R, et al. The impact of an AIDS vaccine in developing countries: a new model and initial results. Health Aff (Millwood) 2007; 26:1147-1158.
5. + T-cell responses represents a major driving force of human immunodeficiency virus type 1 (HIV-1) sequence diversity and reveals constraints on HIV-1 evolution. J Virol 2005; 79:13239-13249.
6. Liu C, Carrington M, Kaslow RA, et al. Association of polymorphisms in human leukocyte antigen class I and transporter associated with antigen processing genes with resistance to human immunodeficiency virus type 1 infection. J Infect Dis 2003; 187:1404-1410.
7. +-T-lymphocyte selection in simian immunodeficiency virus sequence variation. J Virol 2004; 78:14012-14022.
8. + cytotoxic T lymphocyte response. J Exp Med 2004; 200:1243-1256.
9. Price DA, Goulder PJ, Klenerman P, et al. Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection. Proc Natl Acad Sci U S A 1997; 94:1890-1895.
10. Borrow P, Lewicki H, Wei X, et al. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat Med 1997; 3:205-211.
11. Allen TM, O'Connor DH, Jing P, et al. Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia. Nature 2000; 407:386-390.
12. Liu Y, Mullins JI, Mittler JE. Waiting times for the appearance of cytotoxic T-lymphocyte escape mutants in chronic HIV-1 infection. Virology 2006; 347:140-146.
13. Leslie A, Price DA, Mkhize P, et al. Differential selection pressure exerted on HIV by CTL targeting identical epitopes but restricted by distinct HLA alleles from the same HLA supertype. J Immunol 2006; 177:4699-4708. This study illustrates that significant functional differences can exist between CTL that target identical CD8 epitopes when restricted by different HLA alleles.
14. Yu XG, Lichterfeld M, Chetty S, et al. Mutually exclusive T-cell receptor induction and differential susceptibility to HIV-1 mutational escape associated with a two amino acid difference between HLA class I subtypes. J Virol 2007; 81:1619-1631.
15. Price DA, West SM, Betts MR, et al. T cell receptor recognition motifs govern immune escape patterns in acute SIV Infection. Immunity 2004; 21:793-803.
16. Goulder PJ, Phillips RE, Colbert RA, et al. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat Med 1997; 3:212-217.
17. Kelleher AD, Long C, Holmes EC, et al. Clustered mutations in HIV-1 gag are consistently required for escape from HLA-B27-restricted cytotoxic T lymphocyte responses. J Exp Med 2001; 193:375-386.
18. Feeney ME, Tang Y, Pfafferott K, et al. HIV-1 viral escape in infancy followed by emergence of a variant-specific CTL response. J Immunol 2005; 174:7524-7530.
19. Barouch DH, Kunstman J, Kuroda MJ, et al. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature 2002; 415:335-339.
20. Bailey JR, Williams TM, Siliciano RF, Blankson JN. Maintenance of viral suppression in HIV-1-infected HLA-B*57+ elite suppressors despite CTL escape mutations. J Exp Med 2006; 203:1357-1369.
21. Bailey JR, Zhang H, Wegweiser BW, et al. Evolution of HIV-1 in an HLA-B*57-positive patient during virologic escape. J Infect Dis 2007; 196:50-55.
22. Iversen AK, Stewart-Jones G, Learn GH, et al. Conflicting selective forces affect T cell receptor contacts in an immunodominant human immunodeficiency virus epitope. Nat Immunol 2006; 7:179-189.
23. + T-cell responses are mounted in monozygotic twins infected with the same HIV-1 strain. Similar patterns in HIV evolution in these twins also supports constraints on mutational pathways to escape.
24. Moore CB, John M, James IR, et al. Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level. Science 2002; 296:1439-1443.
25. Bhattacharya T, Daniels M, Heckerman D, et al. Founder effects in the assessment of HIV polymorphisms and HLA allele associations. Science 2007; 315:1583-1586. Through use of a phylogenetic approach this study illustrates that viral lineage effects can also influence the identification of HLA-associated mutations at the population level.
26. Timm J, Li B, Daniels MG, et al. HLA associated sequence polymorphisms in HCV reveal reproducible immune responses and constraints on viral evolution. Hepatology 2007; 46:339-349.
27. Brumme ZL, Brumme CJ, Heckerman D, et al. Evidence of differential HLA class I-mediated viral evolution in functional and accessory/regulatory genes of HIV-1. PLoS Pathog 2007; 3: e94 [Epub ahead of print].
28. Addo MM, Yu XG, Rathod A, et al. Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load. J Virol 2003; 77:2081-2092.
29. Frahm N, Korber BT, Adams CM, et al. Consistent cytotoxic-T-lymphocyte targeting of immunodominant regions in human immunodeficiency virus across multiple ethnicities. J Virol 2004; 78:2187-2200.
30. Novitsky V, Cao H, Rybak N, et al. Magnitude and frequency of cytotoxic T-lymphocyte responses: identification of immunodominant regions of human immunodeficiency virus type 1 subtype C. J Virol 2002; 76:10155-10168.
31. Poon AF, Kosakovsky Pond SL, Bennett P, et al. Adaptation to human populations is revealed by within-host polymorphisms in HIV-1 and hepatitis C virus. PLoS Pathog 2007; 3:e45.
32. Gaudieri S, Rauch A, Park LP, et al. Evidence of viral adaptation to HLA class I-restricted immune pressure in chronic hepatitis C virus infection. J Virol 2006; 80:11094-11104.
33. Frater AJ, Brown H, Oxenius A, et al. Effective T-cell responses select human immunodeficiency virus mutants and slow disease progression. J Virol 2007; 81:6742-6751.
34. Horton H, Frank I, Baydo R, et al. Preservation of T cell proliferation restricted by protective HLA alleles is critical for immune control of HIV-1 infection. J Immunol 2006; 177:7406-7415.
35. Herbeck JT, Nickle DC, Learn GH, et al. Human immunodeficiency virus type 1 env evolves toward ancestral states upon transmission to a new host. J Virol 2006; 80:1637-1644. Longitudinal analysis of intrahost divergence revealed a 2- to 3-year period of evolution toward a common ancestral sequence at the start of infection, indicating that HIV recovers certain ancestral features when infecting a new host.
36. Liu Y, McNevin J, Cao J, et al. Selection on the human immunodeficiency virus type 1 proteome following primary infection. J Virol 2006; 80:9519-9529. This was an intensive longitudinal study of viral genetic changes and T-cell immunity in one patient at up to 17 time points during the first 3 years of infection, and in the infecting partner near the time of transmission. The majority of the amino acids undergoing selection in this patient appeared to result from fitness-balanced CTL selection, confirming CTLs as a dominant selective force in HIV-1 infection.
37. Li B, Gladden AD, Altfeld M, et al. Rapid reversion of sequence polymorphisms dominates early human immunodeficiency virus type 1 evolution. J Virol 2007; 81:193-201. This study illustrates that a substantial proportion of amino acid mutations arising during acute HIV-1 infection represent reversions towards consensus residues, suggesting that many transmitted mutations may incur a fitness cost to HIV.
38. Rolland M, Nickle DC, Mullins JI. A new, core elements approach to vaccine immunogen design. PLoS Pathog 2007. In press.
39. Fernandez G, Clotet B, Martinez MA. Fitness landscape of human immunodeficiency virus type 1 protease quasispecies. J Virol 2007; 81:2485-2496.
40. Gandhi RT, Wurcel A, Rosenberg ES, et al. Progressive reversion of human immunodeficiency virus type 1 resistance mutations in vivo after transmission of a multiply drug-resistant virus. Clin Infect Dis 2003; 37:1693-1698.
41. Croteau G, Doyon L, Thibeault D, et al. Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors. J Virol 1997; 71:1089-1096.
42. Martinez-Picado J, Savara AV, Sutton L, D'Aquila RT. Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1. J Virol 1999; 73:3744-3752.
43. Zennou V, Mammano F, Paulous S, et al. Loss of viral fitness associated with multiple Gag and Gag-Pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo. J Virol 1998; 72:3300-3306.
44. Friedrich TC, Dodds EJ, Yant LJ, et al. Reversion of CTL escape-variant immunodeficiency viruses in vivo. Nat Med 2004; 10:275-281.
45. Peyerl FW, Bazick HS, Newberg MH, et al. Fitness costs limit viral escape from cytotoxic T lymphocytes at a structurally constrained epitope. J Virol 2004; 78:13901-13910.
46. Fernandez CS, Stratov I, De Rose R, et al. Rapid viral escape at an immunodominant simian-human immunodeficiency virus cytotoxic T-lymphocyte epitope exacts a dramatic fitness cost. J Virol 2005; 79:5721-5731.
47. Matano T, Kobayashi M, Igarashi H, et al. Cytotoxic T lymphocyte-based control of simian immunodeficiency virus replication in a preclinical AIDS vaccine trial. J Exp Med 2004; 199:1709-1718.
48. Altfeld M, Allen TM. Hitting HIV where it hurts: an alternative approach to HIV vaccine design. Trends Immunol 2006; 27:504-510. This opinion article argues that vaccines designed to focus immune responses against highly conserved regions of HIV-1 that are unable to escape through sequence variation without incurring a cost to viral fitness may enable controlling viral replication to levels that attenuate disease progression and reduce transmission.
49. Martinez-Picado J, Prado JG, Fry EE, et al. Fitness cost of escape mutations in p24 Gag in association with control of human immunodeficiency virus type 1. J Virol 2006; 80:3617-3623.
50. Schneidewind A, Brockman MA, Yang R, et al. Escape from the dominant HLA-B27 restricted CTL response in Gag is associated with a dramatic reduction in HIV-1 replication. J Virol 2007 Sep 5; [Epub ahead of print].
51. Crawford H, Prado JG, Leslie A, et al. Compensatory mutation partially restores fitness and delays reversion of escape mutation within the immunodominant HLA-B*5703-restricted Gag epitope in chronic human immunodeficiency virus type 1 infection. J Virol 2007; 81:8346-8351.
52. Brockman MA, Schneidewind A, Lahaie M, et al. Escape and compensation from early HLA-B57-mediated CTL pressure on HIV-1 Gag alters capsid interactions with cyclophilin A. J Virol 2007 Aug 29; [Epub ahead of print]. This study details the evolution and functional consequences of escape and subsequent compensatory changes in Gag, as well as the mechanisms of fitness loss and recovery within an epitope.
53. Loh L, Batten CJ, Petravic J, et al. In vivo fitness costs of different Gag CD8 T-cell escape mutant simian-human immunodeficiency viruses for macaques. J Virol 2007; 81:5418-5422.
54. Yeh WW, Cale EM, Jaru-Ampornpan P, et al. Compensatory substitutions restore normal core assembly in simian immunodeficiency virus isolates with Gag epitope cytotoxic T-lymphocyte escape mutations. J Virol 2006; 80:8168-8177.
55. Arien KK, Abraha A, Quinones-Mateu ME, et al. The replicative fitness of primary human immunodeficiency virus type 1 (HIV-1) group M, HIV-1 group O, and HIV-2 isolates. J Virol 2005; 79:8979-8990.
56. Arien KK, Vanham G, Arts EJ. Is HIV-1 evolving to a less virulent form in humans? Nat Rev Microbiol 2007; 5:141-151. This review examines whether HIV-1 is slowly becoming attenuated as it adapts to the human population and whether this might explain the distribution of various clades of HIV worldwide.
57. Wilke CO, Wang JL, Ofria C, et al. Evolution of digital organisms at high mutation rates leads to survival of the flattest. Nature 2001; 412:331-333.
58. Yokomaku Y, Miura H, Tomiyama H, et al. Impaired processing and presentation of cytotoxic-t-lymphocyte (CTL) epitopes are major escape mechanisms from CTL immune pressure in human immunodeficiency virus type 1 infection. J Virol 2004; 78:1324-1332.
59. Allen TM, Altfeld M, Yu XG, et al. Selection, transmission, and reversion of an antigen-processing cytotoxic T-lymphocyte escape mutation in human immunodeficiency virus type 1 infection. J Virol 2004; 78:7069-7078.
60. + T-cell responses following cytotoxic T-lymphocyte escape in chronic human immunodeficiency virus type 1 infection. J Virol 2005; 79:12952-12960.
61. Ueno T, Idegami Y, Motozono C, et al. Altering effects of antigenic variations in HIV-1 on antiviral effectiveness of HIV-specific CTLs. J Immunol 2007; 178:5513-5523.
62. + T-cell responses during primary HIV-1 infection that may contribute to the protective effect of specific HLA class I alleles on disease progression.
63. + T lymphocyte responses in simian immunodeficiency virus-infected rhesus monkeys. J Immunol 2006; 176:319-328.
64. Carrington M, O'Brien SJ. The influence of HLA genotype on AIDS. Annu Rev Med 2003; 54:535-551.
65. Altfeld M, Addo MM, Rosenberg ES, et al. Influence of HLA-B57 on clinical presentation and viral control during acute HIV-1 infection. Aids 2003; 17:2581-2591.
66. Goulder PJ, Brander C, Annamalai K, et al. Differential narrow focusing of immunodominant human immunodeficiency virus gag-specific cytotoxic T-lymphocyte responses in infected African and Caucasoid adults and children. J Virol 2000; 74:5679-5690.
67. + T-cell responses is associated with CD4 counts and viral loads, pointing towards a dominant role of Gag-specific responses in the control of HIV.
68. + T-cell epitopes. J Virol 2007; 81:3667-3672.
69. + T-cell responses are associated with control of HIV.
70. + T cell responses is determined by protein-specificity. AIDS Res Hum Retroviruses 2007. In press.
71. Frahm N, Kiepiela P, Adams S, et al. Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes. Nat Immunol 2006; 7:173-178.
72. Huson DH, Bryant D. Application of phylogenetic networks in evolutionary studies. Mol Biol Evol 2006; 23:254-267.